Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCMA-CD24 CAR-T
- Development stage
- Preclinical
- Lead developer
- Huazhong University of Science and Technology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
BCMA-CD24 CAR-T is an experimental bispecific chimeric antigen receptor (CAR) T-cell therapy developed for the treatment of multiple myeloma (MM). It is designed with an IF/THEN logic-gated circuit to overcome the limitations of traditional BCMA-targeted therapies, such as relapse driven by CD24-positive myeloma stem cells, while minimizing off-tumor toxicity. The construct features a constitutively expressed CAR targeting B-cell maturation antigen (BCMA) and an inducible CAR targeting CD24. The expression of the CD24-CAR is driven by a nuclear factor of activated T cells (NFAT) promoter, which is only activated when the BCMA-CAR binds to its target on myeloma cells. This mechanism ensures that the CD24-targeted cytotoxic activity is restricted to the myeloma microenvironment, sparing healthy tissues that widely express CD24.
- Other names
- bispecific BCMA-CD24 CAR-Tactivation-inducible bispecific BCMA-CD24 CAR-Tlogic-gated BCMA-CD24 CAR-T
02
Targets
BCMA (B-cell maturation antigen)CD24 (Cluster of Differentiation 24)
Beyond the preview
Go deeper on BCMA-CD24 CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCMA-CD24 CAR-T.